# Clinical Evaluation of the Nova Max Pro StatSensor Device

Study · id `cardio:ct-nct07392710` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07392710](<https://clinicaltrials.gov/study/NCT07392710>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07392710

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT07392710. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-02-02 (actual); primary completion 2024-12-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT07392710, source copy `cardio:ctgov-nct07392710-2026-02-06`, retrieved 2026-10-26)
- Started: 2023-02-02 (actual) (ClinicalTrials.gov record NCT07392710, source copy `cardio:ctgov-nct07392710-2026-02-06`, retrieved 2026-10-26)
- Primary completion: 2024-12-12 (actual) (ClinicalTrials.gov record NCT07392710, source copy `cardio:ctgov-nct07392710-2026-02-06`, retrieved 2026-10-26)
- Completion: 2024-12-12 (actual) (ClinicalTrials.gov record NCT07392710, source copy `cardio:ctgov-nct07392710-2026-02-06`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT07392710, source copy `cardio:ctgov-nct07392710-2026-02-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07392710-2026-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Evaluation of the Nova Max Pro StatSensor Device
- Condition: Kidney Transplant
- Condition: Kidney Disease, Chronic
- Intervention (Device): Nova Max Pro StatSensor device
- Lead sponsor: Royal Free Hospital NHS Foundation Trust
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Royal Free Hospital NHS Foundation Trust (`cardio:org-royal-free-hospital-nhs-foundation-trust`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 43eb71e7e16b9cee0875ffc032e942f25854555836254b57a0e12b0abe7b44d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
